Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03600038 · ClinicalTrials.gov registry record · NA

Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)

A NA study of Cancer and Smoking, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
NA
Development phase
59
Enrollment target
1
Study location

NCT03600038 is a NA study of Cancer and Smoking that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 59 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03600038, a NA study of Cancer and Smoking, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
NA
Development phase
59 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to determine whether the novel smartphone application designed specifically for cancer patients to quit smoking (Quit2Heal) provides higher quit rates than the current standard smoking cessation app.

Conditions Studied

Interventions

  • BEHAVIORAL Experimental smoking cessation smartphone app
  • BEHAVIORAL Standard of care smoking cessation smartphone app

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2018-04-02
Est. Completion 2019-12-01
Phase NA

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT03600038

The ClinicalTrials.gov registry entry for NCT03600038 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Experimental smoking cessation smartphone app is the first listed.

NCT03600038 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT03600038 about?

NCT03600038 is a clinical study titled "Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)". The goal of this study is to determine whether the novel smartphone application designed specifically for cancer patients to quit smoking (Quit2Heal) provides higher quit rates than the current standard smoking cessation app.

What is the current status of trial NCT03600038?

This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2018-04-02. Estimated completion is 2019-12-01.

What conditions does trial NCT03600038 study?

This clinical trial studies the following conditions: Cancer, Smoking.

What interventions are being tested in trial NCT03600038?

The interventions under investigation include: Experimental smoking cessation smartphone app (BEHAVIORAL), Standard of care smoking cessation smartphone app (BEHAVIORAL).

Who is sponsoring clinical trial NCT03600038?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03600038 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.